Peptide record

TPDB11815

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity standard
39 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11815
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AFP-GFuse Antifungipept CAFPdb AI4AVP dbAMP 3.0
standard
No
A 39-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GLFTLIKGAAKLIGKTVPKKQARLGMNLWLVKLPTNVKT
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C198H341N53O47S1
DCEHSY
LK
4248.27
11.93
8
0
18
+8
0.25
0.192
120.00
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
1.29
7
Residue Composition
number
3
A
1
R
2
N
0
D
0
C
0
E
1
Q
4
G
0
H
2
I
7
L
7
K
1
M
1
F
2
P
0
S
4
T
1
W
0
Y
3
V
Amino Acid Distribution
A: 3 R: 1 N: 2 D: 0 C: 0 E: 0 Q: 1 G: 4 H: 0 I: 2 L: 7 K: 7 M: 1 F: 1 P: 2 S: 0 T: 4 W: 1 Y: 0 V: 3
Chemical Descriptors
39 reviewed residue count
C198H341N53O47S1 sequence-only estimate (linear, free termini)
4248.27 sequence-only estimate (linear, free termini)
11.93 sequence-only estimate (linear, free termini)
+8 sequence-only estimate (linear, free termini)
0.25 sequence-only estimate (linear, free termini)
0.192 sequence-only estimate (linear, free termini)
Evidence Records 18 records
Evidence 1 Activity

Activity

MIC
Antibacterial
4.7 µg/mL

Target

Escherichia coli

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml).
Evidence 2 Activity

Activity

MIC
Antibacterial
4.7 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP

Other

active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 3 Activity

Activity

MIC
Antibacterial
1.1 µg/mL

Target

B. subtilis

Source & Reference

dbAMP DRAMP

Other

active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 4 Activity

Activity

MIC
Antibacterial
1.1 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP

Other

inst E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 5 Activity

Activity

MIC
Antifungal
4.7 µg/mL

Target

Escherichia coli

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml).
Evidence 6 Activity

Activity

MIC
Antifungal
4.7 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 7 Activity

Activity

MIC
Antifungal
1.1 µg/mL

Target

B. subtilis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 8 Activity

Activity

MIC
Antifungal
1.1 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

inst E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 9 Activity

Activity

MIC
Antiparasitic
4.7 µg/mL

Target

Escherichia coli

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml).
Evidence 10 Activity

Activity

MIC
Antiparasitic
4.7 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP

Other

active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 11 Activity

Activity

MIC
Antiparasitic
1.1 µg/mL

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP

Other

active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 12 Activity

Activity

MIC
Antiparasitic
1.1 µg/mL

Target

Candida albicans

Source & Reference

dbAMP 3.0 DRAMP

Other

inst E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 13 Activity

Activity

MIC
Antiviral
4.7 µg/mL

Target

Escherichia coli

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml).
Evidence 14 Activity

Activity

MIC
Antiviral
4.7 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP

Other

active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 15 Activity

Activity

MIC
Antiviral
1.1 µg/mL

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP

Other

active against E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 16 Activity

Activity

MIC
Antiviral
1.1 µg/mL

Target

Candida albicans

Source & Reference

dbAMP 3.0 DRAMP

Other

inst E. coli (MIC 4.7 ug/ml), S. aureus (MIC 4.7 ug/ml), B. subtilis (MIC 1.1 ug/ml), and C. albicans (MIC 1.1 ug/ml). Aslo histamine release.
Evidence 17 Activity

Activity

0% Hemolysis
Toxicity
50 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 50 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Anti-infection peptidomics of amphibian skin. | Mol Cell Proteomics | 2007
Evidence 18 Activity

Activity

(28.6±5.7)% degranulation
Toxicity
50 µg/mL
Cytotoxic
(28.6±5.7)% degranulation | 50 | µg/mL | target cell: Human mast cells

Target

Human mast cells

Source & Reference

NA
DBAASP
Anti-infection peptidomics of amphibian skin. | Mol Cell Proteomics | 2007